News & Media

Newsroom

Newly Published Epilepsia Supplement Highlights Potential of Third Generation Antiseizure Medications to Help More Patients Achieve Seizure Freedom

3.20.2025

SK Biopharmaceuticals Holds Inaugural Global Commercial Alliance Meeting with Partners to Unify Plans of Bringing Cenobamate to Patients in More Than 100 Countries

12.10.2024

SK Life Science, Inc. Presents XCOPRI® (cenobamate tablets) CV Data at the AES 2024 Annual Meeting Showing a Deeper Understanding of Cenobamate’s Dual Mechanism of Action

12.08.2024

Dr. Sunita Misra, MD, PhD, Selected as a Fellow of the American Epilepsy Society for Professional Accomplishment and Deep Commitment to the Field of Epilepsy

12.02.2024

SK Life Science Presents Cenobamate Research at the 2024 American Epilepsy Society (AES) Annual Meeting

11.25.2024

Welcome to the news and information center for SK Life Science, Inc.

To learn more about SK Life Science, please download our corporate fact sheet

For more information about epilepsy, please download this infographic

For more information about Lennox-Gastaut syndrome, please download this fact sheet

X Community Guidelines

LinkedIn Community Guidelines

Bluesky Community Guidelines

SK Life Science at a Glance

Headquarters Location: Paramus, NJ

R&D Begins: 1993

Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group

Number of Employees: 200+ Employees

Disease Category Focus: CNS Disorders and Oncology

Pipeline: 8 compounds under clinical development

Top